VTGN (STOCKS)
Vistagen Therapeutics, Inc. Common Stock
$0.262700
+0.001500 (+0.57%)
Prev close: $0.261200
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Shawn K. Singh
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $12.36M
- Employees
- 57
- P/E (TTM)
- -0.14
- P/B (TTM)
- 0.29
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $1.27M |
| Benefits Costs and Expenses | $70.95M |
| Costs And Expenses | $70.95M |
| Operating Expenses | $73.40M |
| Research and Development | $54.97M |
| Other Operating Expenses | $18.42M |
| Operating Income/Loss | -$72.13M |
| Income/Loss From Continuing Operations After Tax | -$69.69M |
| Income/Loss From Continuing Operations Before Tax | -$69.68M |
| Income Tax Expense/Benefit | $7.00K |
| Net Income/Loss | -$69.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$69.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$69.69M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.83 |
| Diluted Earnings Per Share | -$1.83 |
| Basic Average Shares | 38,073,926 |
| Diluted Average Shares | 38,073,926 |
| Assets | $48.56M |
| Current Assets | $46.94M |
| Cash | $45.40M |
| Other Current Assets | $1.54M |
| Noncurrent Assets | $1.62M |
| Fixed Assets | $427.00K |
| Other Non-current Assets | $1.19M |
| Liabilities | $13.04M |
| Current Liabilities | $12.80M |
| Accounts Payable | $1.54M |
| Wages | $323.00K |
| Other Current Liabilities | $10.94M |
| Noncurrent Liabilities | $249.00K |
| Equity | $35.52M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $35.52M |
| Liabilities And Equity | $48.56M |
| Net Cash Flow From Operating Activities | -$66.44M |
| Net Cash Flow From Operating Activities, Continuing | -$66.44M |
| Net Cash Flow From Investing Activities | -$877.00K |
| Net Cash Flow From Investing Activities, Continuing | -$877.00K |
| Net Cash Flow From Financing Activities | $30.97M |
| Net Cash Flow From Financing Activities, Continuing | $30.97M |
| Net Cash Flow | -$36.34M |
| Net Cash Flow, Continuing | -$36.34M |
| Comprehensive Income/Loss | -$69.69M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$69.69M |
| Other Comprehensive Income/Loss | -$69.69M |